We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
+11.47%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.98B
AUM Growth
+$132M
Cap. Flow
+$20.2M
Cap. Flow %
0.34%
Top 10 Hldgs %
41.51%
Holding
666
New
23
Increased
324
Reduced
223
Closed
42

Top Buys

Rank Stock Value
1
WMT icon
Walmart Inc
WMT
+$142M
2
ASML icon
ASML
ASML
+$117M
3
TSEM icon
Tower Semiconductor
TSEM
+$112M
4
LRCX icon
Lam Research
LRCX
+$88M
5
MU icon
Micron Technology
MU
+$53.9M

Top Sells

Rank Stock Value
1
SNDK
Sandisk
SNDK
+$81.3M
2
LITE icon
Lumentum
LITE
+$72.3M
3
PM icon
Philip Morris
PM
+$40M
4
MSFT icon
Microsoft
MSFT
+$28.5M
5
META icon
Meta Platforms (Facebook)
META
+$27.2M

Sector Composition

Rank Sector Weight
1 Technology 54.47%
2 Communication Services 12.44%
3 Consumer Discretionary 11.77%
4 Consumer Staples 6.03%
5 Healthcare 5.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALX
576
Alexander's
ALX
$1.44B
$8.27K ﹤0.01%
35
-3
-8% -$715
NXRT
577
NexPoint Residential Trust
NXRT
$664M
$8.18K ﹤0.01%
327
-34
-9% -$975
GOOD
578
Gladstone Commercial Corp
GOOD
$631M
$8.13K ﹤0.01%
711
-58
-8% -$680
ENTA icon
579
Enanta Pharmaceuticals
ENTA
$383M
$8.08K ﹤0.01%
640
+75
+13% +$1K
IVVD icon
580
Invivyd
IVVD
$202M
$7.97K ﹤0.01%
6,128
+682
+13% +$1.25K
IMRX icon
581
Immuneering
IMRX
$278M
$7.6K ﹤0.01%
1,442
+174
+14% +$892
KROS icon
582
Keros Therapeutics
KROS
$210M
$7.47K ﹤0.01%
677
+79
+13% +$1.22K
PONY
583
Pony AI Inc
PONY
$2.91B
$7.4K ﹤0.01%
+784
New +$10.8K
NMRA icon
584
Neumora Therapeutics
NMRA
$302M
$7.29K ﹤0.01%
3,737
+455
+14% +$1.18K
ALT icon
585
Altimmune
ALT
$546M
$7.18K ﹤0.01%
2,331
+282
+14% +$1.2K
PBYI icon
586
Puma Biotechnology
PBYI
$422M
$7.17K ﹤0.01%
1,122
+133
+13% +$858
NGNE icon
587
Neurogene
NGNE
$745M
$6.85K ﹤0.01%
340
+38
+13% +$736
BFS
588
Saul Centers
BFS
$891M
$6.84K ﹤0.01%
210
-14
-6% -$464
AHRT
589
AH Realty Trust
AHRT
$533M
$6.75K ﹤0.01%
1,227
-101
-8% -$645
CTNM
590
Contineum Therapeutics
CTNM
$506M
$6.7K ﹤0.01%
513
+59
+13% +$791
VOR icon
591
Vor Biopharma
VOR
$946M
$6.64K ﹤0.01%
372
+42
+13% +$592
LENZ
592
LENZ Therapeutics
LENZ
$156M
$6.29K ﹤0.01%
688
+81
+13% +$1.14K
AUTL
593
Autolus Therapeutics
AUTL
$373M
$6.17K ﹤0.01%
4,473
+532
+13% +$808
ACIU icon
594
AC Immune
ACIU
$229M
$6.17K ﹤0.01%
2,242
+270
+14% +$838
AVXL icon
595
Anavex Life Sciences
AVXL
$224M
$6.12K ﹤0.01%
1,994
+239
+14% +$1.03K
FHTX icon
596
Foghorn Therapeutics
FHTX
$305M
$6.04K ﹤0.01%
1,263
+152
+14% +$834
CADL icon
597
Candel Therapeutics
CADL
$701M
$6K ﹤0.01%
1,224
+146
+14% +$795
EOLS icon
598
Evolus
EOLS
$365M
$5.95K ﹤0.01%
1,447
+174
+14% +$843
CABA icon
599
Cabaletta Bio
CABA
$448M
$5.78K ﹤0.01%
2,149
+258
+14% +$716
NBP
600
NovaBridge Biosciences American Depositary Shares
NBP
$207M
$5.71K ﹤0.01%
2,321
+279
+14% +$934
22 23
24
25 26

Similar funds

CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.03B AUM 40.55% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return

GF Fund Management's Q1 2026 Portfolio in Review

As of Q1 2026, GF Fund Management held 666 positions worth $5.98B, up 2.3% from $5.85B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

GF Fund Management's Q1 2026 filing shows 23 new, 324 increased, 223 reduced and 42 closed positions. Its largest new stake was Coherent: 98,000 shares worth $23.3M. The largest sale was Sandisk, an estimated $81.3M.

By sector, the portfolio is most concentrated in Technology at 54% of assets, up from 51% a quarter earlier, followed by Communication Services and Consumer Discretionary.

  • GF Fund Management's largest Q1 2026 buy was Coherent: 98,000 shares worth $23.3M.
  • GF Fund Management added most to Walmart Inc in Q1 2026, an estimated $142M increase.
  • GF Fund Management's biggest Q1 2026 reduction was Sandisk, cutting an estimated $81.3M.
  • GF Fund Management fully exited AstraZeneca in Q1 2026, selling an estimated $12.4M.
  • GF Fund Management's ten largest holdings make up 42% of its $5.98B portfolio in Q1 2026.
  • GF Fund Management opened 23 new positions and closed 42 in Q1 2026.
  • GF Fund Management's portfolio value rose 2.3% quarter-over-quarter to $5.98B.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.